ACP-105 Androxepen Research Overview
What Is ACP-105 Androxepen?
ACP-105 Androxepen is a non-steroidal selective androgen receptor modulator investigated in laboratory and preclinical models involving androgen-receptor activation, tissue-selective signalling, metabolic profiling and specialised neurological endpoints.
The correct scientific abbreviation is ACP-105. The compound may also appear as ACP105 without the hyphen. It should not be written as APC-105, which reverses two letters and can interfere with literature searches, product identification and SEO consistency.
Androxepen is the commercial product name used by BioPlex Peptides for its ACP-105 research capsules.
ACP-105 belongs to a structurally distinctive group of non-steroidal androgen-receptor ligands. Unlike many arylpropionamide SARMs, its molecular structure includes an azabicyclooctane-associated system.
The principal molecular characteristics of ACP-105 include:
Compound name—ACP-105, Commercial name—Androxepen, Alternative form—ACP105, Research classification—Non-steroidal selective androgen receptor modulator, Molecular formula—C₁₆H₁₉ClN₂O, Approximate molecular weight—290.79 g/mol, Principal research target—Androgen receptor.
ACP-105 is a genuine SARM because its principal molecular activity involves androgen-receptor modulation.
This distinguishes it from compounds such as MK-677 Ibutamoren, Cardarine GW-501516, SR-9009 and SR-9011, which are commonly grouped with SARMs commercially but operate through different molecular targets.
Researchers searching for ACP-105 UK, ACP-105 for sale UK, buy ACP-105 UK or where to buy ACP-105 should understand that its evidence base remains principally laboratory and preclinical.
This ACP-105 research overview examines its partial-agonist profile, tissue selectivity, structural characteristics, metabolic research, specialised neurological models, analytical identity and current evidence limitations.
How ACP-105 Works in Research
ACP-105 is investigated as a ligand of the androgen receptor.
The androgen receptor is a ligand-activated nuclear receptor involved in androgen-responsive gene transcription. It can be activated by steroidal androgens and by compatible non-steroidal ligands.
Before ligand binding, the androgen receptor is generally associated with chaperone proteins within the cellular interior.
When ACP-105 interacts with the receptor, several connected events may occur.
These events can include:
Ligand binding, Receptor conformational change, Reorganisation of regulatory proteins, Nuclear translocation, Interaction with androgen-response elements, Recruitment of transcriptional co-regulators, Altered androgen-responsive gene expression.
ACP-105 was identified during research into non-steroidal compounds capable of producing potent androgen-receptor activity while displaying different responses across separate tissues.
Original compound-characterisation research described ACP-105 as a potent, selective androgen-receptor modulator with partial-agonist activity relative to a reference androgen.
Partial agonism requires careful explanation.
A partial agonist activates a receptor but may produce a lower maximum response than a full agonist under the same experimental conditions. This does not mean that a partial agonist is universally weak or inactive.
Its behaviour can vary according to receptor density, ligand concentration, competing molecules, cell type and availability of transcriptional co-regulators.
What Partial Agonism Means for ACP-105
Receptor activity is not limited to a simple choice between completely active and completely inactive.
A ligand can produce different degrees of receptor activation.
A full agonist may produce the maximum response available within a particular assay system. A partial agonist can activate the same receptor while producing a lower maximum response under equivalent conditions.
An antagonist may bind without producing the same activating response and can interfere with activation produced by another ligand.
ACP-105 has been investigated using cell-based androgen-receptor assays to examine its potency, efficacy and selectivity.
Relevant partial-agonist research measurements include:
Receptor-binding affinity, Concentration-response curves, Maximum transcriptional response, Half-maximal effective concentration, Co-activator recruitment, Competition with reference ligands, Tissue-specific gene expression.
A compound can appear highly potent because a low concentration produces a measurable response while still having a lower maximum efficacy than a reference full agonist.
Researchers should therefore distinguish potency from efficacy.
Potency concerns the concentration required to produce a specified response. Efficacy concerns the maximum response that the compound can produce within the selected assay.
Marketing descriptions frequently treat these concepts as though they mean the same thing. They do not.
Tissue Selectivity in ACP-105 Research
Tissue selectivity describes relative differences in androgen-receptor-associated activity across separate tissues or experimental environments.
It does not mean that ACP-105 acts exclusively in skeletal-muscle or bone models.
Preclinical ACP-105 research has examined whether the compound produces a different balance of activity across muscle, bone and reproductive-tissue measurements.
Tissue-selective activity may be influenced by:
Androgen-receptor concentration, Transcriptional co-activators, Transcriptional co-repressors, Ligand metabolism, Tissue distribution, Receptor conformation, Baseline endocrine conditions, Exposure duration, Gene accessibility.
The same ACP-105 concentration may produce different responses across different cell types because each cellular environment contains a distinct combination of receptors, enzymes and transcriptional regulators.
Selectivity is therefore a relative experimental profile rather than a guarantee of activity restricted to one tissue.
Researchers should evaluate multiple tissues, concentrations and endpoints before describing a compound as tissue selective.
What Researchers Study ACP-105 For
ACP-105 has been investigated in several connected areas of androgen-receptor research.
Principal ACP-105 research areas include:
Androgen-receptor binding, Partial-agonist activity, Tissue-selective transcription, Skeletal-muscle-associated endpoints, Bone-associated measurements, Metabolic profiling, Metabolite identification, Pharmacokinetic prediction, Neurological models, Cognitive-associated measurements, Analytical detection.
The evidence is not distributed equally across these areas.
Some published work focuses on compound discovery and receptor characterisation. Other research examines specialised preclinical neurological models or the detection of ACP-105 and its metabolites.
These studies should be interpreted according to their individual objectives rather than merged into one general claim.
ACP-105 and Skeletal-Muscle Research
Early preclinical characterisation examined ACP-105 within androgen-responsive tissue models.
Researchers may evaluate whether the compound produces measurable activity within skeletal-muscle-associated tissues while displaying a different response profile elsewhere.
Potential skeletal-muscle measurements include:
Androgen-responsive muscle weight, Lean-tissue measurements, Muscle-fibre dimensions, Androgen-receptor expression, Transcriptional markers, Protein-expression variables, Functional-force measurements.
An increase in one tissue measurement should not automatically be interpreted as a universal change across every skeletal-muscle group.
Tissue weight, molecular signalling and functional performance are separate endpoints. Strong experimental designs combine structural, molecular and functional measurements.
The baseline endocrine state of the model also matters. Activity observed under experimentally altered androgen conditions may differ from activity in an unaltered baseline system.
ACP-105 and Bone-Associated Research
The androgen receptor participates in pathways associated with bone formation, maintenance and remodelling.
ACP-105 has been discussed in preclinical research involving tissue-selective activity across muscle and bone-associated models.
Bone-related measurements may include:
Bone mineral density, Bone mineral content, Cortical thickness, Trabecular structure, Mechanical-strength testing, Osteoblast-associated markers, Osteoclast-associated markers, Bone-turnover variables.
Bone mineral density does not independently describe every aspect of bone quality.
Microarchitecture, mineral distribution and mechanical strength also contribute to structural interpretation.
Researchers should avoid converting preliminary bone-associated measurements into universal claims. Results remain dependent on species, model, exposure duration and analytical technique.
ACP-105 and Specialised Neurological Models
ACP-105 has also appeared in specialised preclinical research involving cognitive, behavioural and neurological measurements.
These investigations distinguish ACP-105 from SARMs discussed almost exclusively through skeletal or body-composition research.
Some studies examined ACP-105 alone or alongside a selective oestrogen-receptor beta agonist in models involving cognitive deficits, amyloid-associated measurements and behaviour.
Other research examined motor performance and fear-conditioning endpoints after experimentally induced neurological stress.
Relevant measurements have included:
Spatial-memory variables, Motor coordination, Fear-conditioning responses, Anxiety-like behaviour, Amyloid-associated markers, Neurological gene expression, Activity measurements.
These findings remain specialised and model-specific.
A behavioural change observed in one preclinical model does not establish a general cognitive effect. Results can be influenced by locomotor activity, stress, sensory function, experimental timing and baseline condition.
Researchers must also distinguish activity associated with ACP-105 alone from responses observed when ACP-105 is combined with another experimental compound.
ACP-105 Metabolism and ADME Research
ADME refers to absorption, distribution, metabolism and excretion.
Understanding these processes helps researchers determine how a compound moves through an experimental system, which metabolites are formed and how exposure relates to measurable responses.
ACP-105 metabolism has been examined in forensic and anti-doping research. Laboratory investigations have used mass-spectrometry methods to identify the parent compound and proposed metabolites.
More recent computational research has examined predicted absorption, protein binding, tissue distribution, enzyme interactions and clearance.
Relevant ADME variables include:
Absorption, Plasma-protein binding, Tissue distribution, Metabolic enzymes, Oxidation, N-dealkylation, Conjugation, Predicted clearance, Metabolite formation.
Computational ADME predictions should not be treated as equivalent to directly measured pharmacokinetic data.
They provide hypotheses that can guide laboratory research, but experimental validation remains necessary.
Likewise, metabolic findings from one species or model should not automatically be transferred to another system.
ACP-105 and Metabolite Identification
Metabolite research is important for analytical identification and forensic monitoring.
After a compound enters a biological research system, enzymes may convert it into related molecular structures. Some metabolites may retain biological activity, while others may be inactive or eliminated more readily.
Researchers have investigated ACP-105 metabolism using liquid chromatography combined with tandem mass spectrometry.
Metabolic changes may include:
Hydroxylation, Oxidation, N-dealkylation, Conjugation, Multiple-step transformations.
The parent compound may not always be the most persistent analytical marker.
Metabolite profiling can help researchers select suitable detection targets and understand why different samples produce different analytical patterns.
Metabolic pathways may also vary according to species, enzyme expression, sampling time and exposure conditions.
ACP-105 Compared With AC-262,536
ACP-105 and AC-262,536 are separate selective androgen receptor modulators.
Their names are sometimes confused because both compounds are associated with ACADIA Pharmaceuticals and contain the letters AC within their development codes.
AC-262,536 is commonly called Accadrine. ACP-105 is sold by BioPlex under the commercial name Androxepen.
They do not share the same molecular formula or molecular structure.
The principal distinction is:
ACP-105 ⟶ Androxepen ⟶ C₁₆H₁₉ClN₂O
AC-262,536 ⟶ Accadrine ⟶ C₁₈H₁₈N₂O
Both compounds have been investigated as non-steroidal androgen-receptor modulators, but findings obtained with one should not automatically be applied to the other.
Accurate naming is essential when searching published research, reviewing analytical documentation or comparing products.
ACP-105 Compared With RAD-140 and Ostarine
ACP-105 is sometimes compared with RAD-140 Testolone and Ostarine MK-2866 because all three compounds are genuine androgen-receptor modulators.
However, their molecular structures and evidence profiles differ.
Ostarine has a more extensive clinical-research history involving lean-tissue and functional endpoints. RAD-140 has published preclinical characterisation and specialised clinical investigation.
ACP-105 has a smaller evidence base focused on compound characterisation, preclinical tissue selectivity, specialised neurological models, metabolism and analytical detection.
This does not make ACP-105 scientifically irrelevant. It means its claims must be matched to the evidence available for ACP-105 itself.
Researchers should not assume that findings from Ostarine or RAD-140 apply to ACP-105 simply because all three are SARMs.
How Researchers Identify ACP-105
Correct analytical identification is essential because ACP-105 may be confused with APC-105 or AC-262,536.
HPLC can be used to examine chromatographic purity. Liquid chromatography–mass spectrometry can support molecular-identity and metabolite analysis. Nuclear magnetic resonance spectroscopy may provide more detailed structural confirmation.
Relevant analytical information includes:
Correct ACP-105 name, Molecular formula, Expected molecular mass, Chemical structure, Chromatographic purity, Mass-spectrometry identity, Batch number, Capsule strength, Content uniformity, Storage information.
Purity and identity are separate measurements.
A dominant chromatographic peak may support a high-purity result, but identity testing is necessary to demonstrate that the detected material is ACP-105.
For capsule research, content-uniformity testing can determine whether the declared amount is distributed consistently across the batch.
What Should Researchers Check When Buying ACP-105 in the UK?
Researchers searching for ACP-105 for sale UK, buy ACP-105 UK, ACP-105 capsules UK or where to buy ACP-105 should first check that the compound is named correctly.
The supplier should use ACP-105 rather than APC-105.
Researchers should also examine:
Correct compound name, Molecular formula C₁₆H₁₉ClN₂O, Approximate molecular weight 290.79 g/mol, Declared capsule strength, Number of capsules, Batch information, Purity documentation, Identity testing, Capsule-content uniformity, UK manufacturing or encapsulation information, Research-use classification, Supplier traceability.
The BioPlex ACP-105 Androxepen research product provides 50 capsules with a declared strength of 15mg per capsule for controlled laboratory and analytical research.
The current product URL contains the earlier APC-105 spelling. It should remain accessible if corrected, either as the retained URL or through a permanent redirect to a new ACP-105 handle.
Researchers comparing SARMs for sale UK should not select materials according to price or promotional descriptions alone.
Chemical identity, analytical documentation, batch consistency and technically accurate naming are essential for reproducible research.
Limitations of Current ACP-105 Research
ACP-105 has a smaller evidence base than Ostarine, LGD-4033 or several other well-known SARMs.
Important limitations include:
Limited controlled clinical evidence, Reliance on cellular and preclinical models, Small number of direct compound studies, Model-specific neurological findings, Limited experimentally measured pharmacokinetic data, Reliance on computational ADME predictions, Differences between research material and commercial products, Incomplete long-term characterisation.
Results from specialised neurological models should not be generalised to unrelated research settings.
Computational metabolism and toxicity predictions require experimental validation. Likewise, findings from forensic or anti-doping research are valuable for detection but do not independently establish every biological property of the compound.
Future research would benefit from independent receptor studies, broader pharmacokinetic analysis, standardised analytical identification and replication across multiple models.
Conclusion
ACP-105 Androxepen is a non-steroidal selective androgen receptor modulator investigated for potent receptor activity, partial agonism, tissue-selective signalling, metabolism and specialised neurological endpoints.
Its molecular formula is C₁₆H₁₉ClN₂O and its approximate molecular weight is 290.79 g/mol.
ACP-105 is the correct scientific abbreviation. APC-105 is a spelling error and should be corrected across product titles, technical specifications, internal links and future content.
ACP-105 is a genuine SARM because it operates through androgen-receptor modulation. However, its evidence profile is smaller and more specialised than those of Ostarine or LGD-4033.
Researchers should distinguish potency from efficacy, partial agonism from inactivity and tissue selectivity from activity limited to one tissue.
Researchers considering ACP-105 for sale UK should examine correct naming, molecular identity, capsule strength, batch documentation, chromatographic purity, mass-spectrometry evidence and supplier transparency.
Continue Exploring...
Explore ACP-105 Androxepen Research Capsules ⟶
Explore the BioPlex SARMs Research Collection ⟶
Read the Complete SARMs UK Research Compound Guide ⟶
Read the S-4 Andarine Research Overview ⟶
Learn More About BioPlex Peptides ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
